These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27232918)

  • 1. Are BVS suitable for ACS patients? Support from a large single center real live registry.
    Felix CM; Onuma Y; Fam JM; Diletti R; Ishibashi Y; Karanasos A; Everaert BRC; van Mieghem NMDA; Daemen J; de Jaegere PPT; Zijlstra F; Regar ES; van Geuns RJM
    Int J Cardiol; 2016 Sep; 218():89-97. PubMed ID: 27232918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes.
    Gori T; Schulz E; Hink U; Kress M; Weiers N; Weissner M; Jabs A; Wenzel P; Capodanno D; Münzel T
    JACC Cardiovasc Interv; 2015 May; 8(6):770-777. PubMed ID: 25999097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and angiographic outcome of a single center, real world population treated with a dedicated technique of implantation for bioresorbable vascular scaffolds. The FAtebenefratelli Bioresorbable Vascular Scaffold (FABS) registry.
    Cortese B; di Palma G; Cerrato E; Latini RA; Elwany M; Orrego PS; Seregni RG
    J Interv Cardiol; 2017 Oct; 30(5):427-432. PubMed ID: 28853189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year clinical performance of ABSORB bioresorbable vascular scaffold in patients presenting with acute coronary syndromes: Results from the RAI registry.
    Moscarella E; Ielasi A; Varricchio A; Cortese B; Loi B; Tarantini G; Pisano F; Durante A; Pasquetto G; Colombo A; Tumminello G; Moretti L; Calabrò P; Mazzarotto P; Tespili M; Silva Orrego P; Corrado D; Steffenino G;
    Catheter Cardiovasc Interv; 2019 Feb; 93(3):404-410. PubMed ID: 30346080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus eluting bioresorbable vascular scaffolds in patients with acute coronary syndromes: Two-year results from the German-Austrian ABSORB registry.
    Tröbs M; Achenbach S; Nef HM; Gori T; Naber C; Neumann T; Richardt G; Schmermund A; Wöhrle J; Zahn R; Hamm CW;
    Catheter Cardiovasc Interv; 2021 Oct; 98(4):E564-E570. PubMed ID: 34137482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry.
    Kraak RP; Hassell ME; Grundeken MJ; Koch KT; Henriques JP; Piek JJ; Baan J; Vis MM; Arkenbout EK; Tijssen JG; de Winter RJ; Wykrzykowska JJ
    EuroIntervention; 2015 Feb; 10(10):1160-8. PubMed ID: 25136885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous coronary interventions with the Absorb Bioresorbable vascular scaffold in real life: 1-year results from the FRANCE ABSORB registry.
    Cayla G; Koning R; Fajadet J; Sainsous J; Carrié D; Elhadad S; Tarragano F; Lefévre T; Ranc S; Ghostine S; Garot P; Marco F; Maillard L; Motreff P; Le Breton H;
    Arch Cardiovasc Dis; 2019 Feb; 112(2):113-123. PubMed ID: 30630761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of bioresorbable vascular scaffold to treat all-comer patients. Are patients with acute coronary syndrome better candidates for bioresorbable vascular scaffold?
    Picard F; Avram R; Marquis-Gravel G; Tadros VX; Ly HQ; Dorval JF; Doucet S; Gosselin G; Asgar AW; Ibrahim R; Bonan R; de Hemptinne Q; Nosair M; L-L'Allier P; Tanguay JF
    Cardiovasc Revasc Med; 2019 Mar; 20(3):228-234. PubMed ID: 30075958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of bioresorbable vascular scaffolds in acute coronary syndrome: A two-center, one-year follow-up analysis.
    Iwańczyk S; Hiczkiewicz J; Araszkiewicz A; Łanocha M; Adamczak D; Faron W; Grajek S; Lesiak M
    Cardiol J; 2018; 25(4):479-486. PubMed ID: 29168541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicenter GHOST-EU Extended Registry.
    Schnorbus B; Wiebe J; Capodanno D; Brugaletta S; Geraci S; Mehilli J; Latib A; Lesiak M; Jensen C; Mattesini A; Münzel T; Capranzano P; Di Mario C; Naber C; Araszkiewicz A; Colombo A; Caramanno G; Sabate M; Tamburino C; Nef H; Gori T
    EuroIntervention; 2017 Oct; 13(9):e1104-e1111. PubMed ID: 28320687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry.
    Baumbach A; Zaman A; West NEJ; O'Kane P; Egred M; Johnson T; Wheatcroft S; Bowles R; de Belder A; Bouras G; Lansky A; Hill J; Mathur A; de Belder MA; Banning AP
    EuroIntervention; 2018 Jan; 13(13):1554-1560. PubMed ID: 29131802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Clinical Presentation on Early Vascular Healing After Bioresorbable Vascular Scaffold Implantation.
    Baquet M; Brenner C; Wenzler M; Eickhoff M; David J; Brunner S; Theiss H; Massberg S; Guagliumi G; Mehilli J
    J Interv Cardiol; 2017 Feb; 30(1):16-23. PubMed ID: 27896843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implantation of bioresorbable vascular scaffolds following acute coronary syndrome is associated with reduced early neointimal growth and strut coverage.
    Giblett JP; Brown AJ; Keevil H; Jaworski C; Hoole SP; West NE
    EuroIntervention; 2016 Aug; 12(6):724-33. PubMed ID: 27542784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients With Chronic Total Coronary Occlusions: Acute Procedural and Short-Term Clinical Results.
    Goktekin O; Yamac AH; Latib A; Tastan A; Panoulas VF; Sato K; Erdogan E; Uyarel H; Shah I; Colombo A
    J Invasive Cardiol; 2015 Oct; 27(10):461-6. PubMed ID: 26429848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate and long-term clinical performance of bioresorbable vascular scaffolds in a real world population.
    Maggio S; Zanetti C; Pesarini G; Zivelonghi C; Piccoli A; Gambaro A; Scarsini R; Cuman M; Vassanelli C; Ribichini F
    Minerva Cardioangiol; 2016 Aug; 64(4):404-10. PubMed ID: 26963445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-Year Clinical and Computed Tomography Angiographic Outcomes After Bioresorbable Vascular Scaffold Implantation During Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: The PRAGUE-19 Study.
    Widimsky P; Petr R; Tousek P; Maly M; Linkova H; Vrana J; Hajsl M; Budesinsky T; Lisa L; Kocka V
    Circ Cardiovasc Interv; 2015 Dec; 8(12):e002933. PubMed ID: 26628591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of bioresorbable vascular scaffolds in patients with stable angina and acute coronary syndromes. Polish National Registry.
    Rzeszutko Ł; Siudak Z; Włodarczak A; Lekston A; Depukat R; Ochała A; Gil RJ; Balak W; Marć M; Kochman J; Zasada W; Dudek D
    Kardiol Pol; 2014; 72(12):1394-9. PubMed ID: 25001567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical results of single and multiple bioresorbable drug-eluting scaffolds for treatment of de-novo coronary artery disease.
    Markovic S; Dragomir S; Walcher D; Bernhardt P; Imhof A; Rottbauer W; Wöhrle J
    Coron Artery Dis; 2016 Nov; 27(7):561-5. PubMed ID: 27244371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct Absorb bioresorbable scaffold implantation in acute coronary syndrome.
    Rzeszutko Ł; Węgiel M; Kleczyński P; Zasada W; Depukat R; Rakowski T; Legutko J; Surdacki A; Dudek D; Bartuś S
    Kardiol Pol; 2018; 76(10):1434-1440. PubMed ID: 30067276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study.
    Fam JM; Felix C; van Geuns RJ; Onuma Y; Van Mieghem NM; Karanasos A; van der Sijde J; De Paolis M; Regar E; Valgimigli M; Daemen J; de Jaegere P; Zijlstra F; Diletti R
    EuroIntervention; 2016 May; 12(1):30-7. PubMed ID: 27173859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.